StockWatch
·

FDC LTD. Q1 FY27 Results

FDCQ1 FY27 Results
Filing
Result:Good· Market: DownMargin expansion
MetricValueQ4 FY26Q1 FY26
Revenue667.69 Cr14.2%3.0%
Total Income715.35 Cr12.7%4.6%
Expenditure540.65 Cr9.4%3.1%
PBT174.70 Cr24.5%9.3%
Net Profit132.49 Cr28.1%9.2%
OPM21.42%3.23pp0.22pp
NPM18.52%2.23pp0.78pp
EPS8.1428.2%9.3%
View full financials

Pharma core revenue growth was weak at 3% YoY with flat operating margin, but adjusted PAT rose 9.2% YoY to a 6-quarter high with NPM expanding to 18.52%, landing this in the healthy-but-not-standout good band since profit growth was aided by a 34% jump in other income rather than core operating leverage.

Q1 FY-2027 RESULTS · FDC

FDC Q1 FY27: consol PAT +9% YoY to ₹132 Cr on margin gains; revenue growth slows to 3%

PAT +9.18% YoY · revenue +2.97% · margins expanding

05 Aug 2026 · 3 min read
Revenue

₹667.69 Cr

+2.97% YoY

PAT (consolidated)

₹132.49 Cr

+9.18% YoY

Net margin

18.52%

+0.8pp YoY

EPS

₹8.14

FDC Ltd's consolidated Q1 FY27 (quarter ended June 30, 2026) print is profit-led rather than volume-led: consolidated PAT rose 9.2% YoY to ₹132.49 Cr on revenue growth of just 3.0% YoY to ₹667.69 Cr, with net margin expanding to 18.52% from 17.74% a year ago. Operating margin (PBT before exceptional items, adjusted for finance cost, depreciation and other income, over revenue) held roughly flat at 21.42% versus 21.64% a year ago — so the earnings growth was driven mainly by a 34.2% YoY jump in other income (₹47.65 Cr vs ₹35.50 Cr) rather than by core operating leverage. Sequentially the quarter looks stronger, with PAT up 28.1% QoQ and revenue up 14.2% QoQ against a soft Q4 FY26, but per our reading convention that QoQ move is supporting detail, not the headline story.

The scoreboard

Q1 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹667.69 Cr+14.2%+3%
Expenses₹540.65 Cr+9.4%+3.2%
PAT₹132.49 Cr+28.13%+9.18%
Net margin18.52%+2.2pp+0.8pp
EPS₹8.14+28.2%+9.3%

Standalone growth diverges sharply from the consolidated picture: standalone revenue grew 20.8% YoY to ₹655.10 Cr against consolidated revenue growth of only 3.0% YoY, implying the net inter-company/subsidiary contribution — which the auditors describe as immaterial to the group this quarter at ₹17.21 Cr of pre-consolidation subsidiary revenue — was unusually elevated in the year-ago quarter. Readers comparing the standalone and consolidated releases should expect the topline growth rates to look very different this quarter for that reason; standalone PAT itself grew a similar 8.0% YoY to ₹132.02 Cr, in line with the consolidated PAT trend.

348.96372.57396.18419.78443.39408.9505-0405-2506-1707-1008-0308-05Q1 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹408.95, down 4% over the past month of trading.

₹ Cr
049.4698.93148.3938.67Q4 FY25rev ₹492 Cr121.35Q1 FY26rev ₹648 Cr28.37Q2 FY26rev ₹473 Cr28.3Q3 FY26rev ₹465 Cr103.4Q4 FY26rev ₹585 Cr132.49Q1 FY27rev ₹668 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

Beyond the headline

What the summary numbers don't show

NPM expanded to 18.52% from 17.74% YoY (+0.78pp) and 16.29% QoQ (+2.23pp) — OPM ~21.42% vs 21.64% YoY (flat) and 18.19% QoQ (+3.23pp)

Consolidated EPS ₹8.14 vs ₹7.45 a year ago — standalone EPS ₹8.11 vs ₹7.51

No exceptional items in current or year-ago quarter — FY26's actuarial exceptional charge (₹20.79 Cr) and fair-value swing were confined to Q4 FY26

We have no analyst consensus estimates on record and a web search turned up no published Q1 FY27 preview or brokerage estimate for FDC specifically, so vsStreet is marked unknown rather than assumed. Similarly, there is no formal management guidance on record for this quarter — company records and search show none — so vsGuidance is also unknown. No separate management press release with qualitative commentary was available in the context to cross-check against the numbers; the filing itself is limited to the regulatory disclosure and financial statements.

  • W1

    Whether the standalone-vs-consolidated revenue growth gap (+20.8% vs +3.0% YoY) normalizes or recurs in Q2 FY27

  • W2

    Operating margin trajectory — flat YoY at ~21.4% while NPM-led earnings growth continues; watch if OPM itself expands in coming quarters

  • W3

    Outcome of Maharashtra FDA's June 4, 2026 seizure of 'Enerzal' stock and samples — no quantified impact disclosed yet

Informational and educational content only. Not investment advice.

FDC LTD. (FDC) Q1 FY27 Results — StockWatch